[干细胞移植治疗对慢性心力衰竭患者预防心脏重构及主要心血管不良事件疗效的荟萃分析]

[A meta-analysis on the efficacy of stem cells transplantation therapy on the prevention of cardiac remodeling and main adverse cardiovascular event in patients with chronic heart failure].

作者信息

He Wei, Wang Guan, Quan Xiao-Qing, Zhang Cun-Tai, Xie Dong-Ming, Yang Yi-Hong, Yang Xiao-Ling, Liu Xian-Fa

机构信息

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

出版信息

Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Apr;41(4):282-7.

PMID:23906396

Abstract

OBJECTIVE

Stem cells transplantation is a promising strategy in cardiology. This meta-analysis summarizes the efficacy and safety of stem cells transplantation on top of standard medication on chronic heart failure patients.

METHODS

The following databases were searched, including Cochrane Library (Issue 4, 2011), PubMed (1980 to 2011), Embase (1990 to 2011), CBM (1978 to 2011), CNKI (1994 to 2011), VIP (1989 to 2011), and WanFang Data (1998 to 2011). Search criteria:studies were screened and the quality was evaluated according to predefined inclusion and exclusion criteria. Intervention measures: the treatment group using stem cell transplantation therapy on top of standard drug treatment, while the control group using standard drug treatments.

RESULTS

A total of 31 studies involving 2375 patients were included. The results show that the improvement of LVEDV in the stem cell treatment group is greater than in the control group [SMD = -11.8% (95%CI: -0.223 - 0.013), P = 0.027] and the relative-risk of cardiac events is lower in stem cell treatment group [RR = 0.77 (95%CI: 0.66 - 0.90), P < 0.01] than in control group.

CONCLUSION

Stem cells therapy is effective in improving cardiac remodeling and reducing the relative-risk of cardiac events in patients with chronic heart failure.

摘要

目的

干细胞移植是心脏病学中一种很有前景的治疗策略。本荟萃分析总结了在标准药物治疗基础上进行干细胞移植对慢性心力衰竭患者的疗效和安全性。

方法

检索了以下数据库，包括Cochrane图书馆（2011年第4期）、PubMed（1980年至2011年）、Embase（1990年至2011年）、中国生物医学文献数据库（1978年至2011年）、中国知网（1994年至2011年）、维普资讯（1989年至2011年）和万方数据（1998年至2011年）。检索标准：根据预先设定的纳入和排除标准筛选研究并评估质量。干预措施：治疗组在标准药物治疗基础上采用干细胞移植疗法，而对照组采用标准药物治疗。

结果

共纳入31项研究，涉及2375例患者。结果显示，干细胞治疗组左室舒张末期容积的改善程度大于对照组[标准化均数差=-11.8%（95%可信区间：-0.223至0.013），P=0.027]，且干细胞治疗组心脏事件的相对风险低于对照组[相对危险度=0.77（95%可信区间：0.66至0.90），P<0.01]。